3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
11
Other hematologic neoplasm
3
Sarcoma
2
Plasma cell
2
Head & Neck
2
Gastrointestinal
2
Dermatologic
2
CNS
2
Breast
2
Thoracic
1
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
86
Lung Neoplasms
32
Small Cell Lung Carcinoma
18
Melanoma
17
Mesothelioma
13
Neoplasms
11
Colorectal Neoplasms
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
7
Neoplasm Metastasis
7
Mesothelioma, Malignant
7
Carcinoma, Transitional Cell
7
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Kidney Neoplasms
4
Brain Neoplasms
4
Carcinoma, Merkel Cell
3
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Interventions
pembrolizumab
8
Nivolumab
6
Gemcitabine
5
spartalizumab
3
Magnetic Resonance Spectroscopy
3
Cyclophosphamide
3
Azacitidine
3
toripalimab
2
fludarabine
2
epacadostat
2
atezolizumab
2
Therapeutics
2
Sirolimus
2
Paclitaxel
2
Interleukin-2
2
Epoetin Alfa
2
Cisplatin
2
Bevacizumab
2
vocimagene amiretrorepvec
1
vandetanib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
temsirolimus
1
sargramostim
1
sapanisertib
1
ruxolitinib
1
rucaparib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Ipilimumab
×
Thoracic
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts